7.1 Regulatory Submissions (IND, NDA, IDE, PMA)

Introduction to Regulatory Submissions

In the United States, the Food and Drug Administration (FDA) is the regulatory authority responsible for ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. The pathway from laboratory discovery to market availability involves rigorous testing and documentation. This process is governed by specific regulatory submissions. For a Clinical Research Coordinator (CCRC), understanding these submissions is critical because the data collected at the clinical site directly informs these applications.

There are distinct pathways for drugs/biologics versus medical devices. Drugs follow the Investigational New Drug (IND) and New Drug Application (NDA) or Biologics License Application (BLA) pathways. Devices follow the Investigational Device Exemption (IDE) and Premarket Approval (PMA) or 510(k) clearance pathways.

---

Drugs and Biologics: The IND Pathway

Before a new drug can be tested in humans, a sponsor must submit an Investigational New Drug (IND) application to the FDA. The IND acts as a request for an exemption from the federal statute that prohibits an unapproved drug from being transported across state lines.

Components of an IND

An IND submission is a massive compilation of preliminary data, including:

• Animal Pharmacology and Toxicology Studies: Preclinical data demonstrating that the product is reasonably safe for initial testing in humans. This includes pharmacokinetic (PK) and pharmacodynamic (PD) profiles in animal models.
• Manufacturing Information: Detailed descriptions of the composition, manufacturer, stability, and controls used for manufacturing the drug substance and the drug product. This ensures the company can adequately produce and supply consistent batches of the drug.
• Clinical Protocols and Investigator Information: Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks. Information on the qualifications of clinical investigators (usually through Form FDA 1572) is also required.

The 30-Day Wait Period

Once the FDA receives the IND, there is a mandatory 30-day review period. During this time, the FDA reviews the application to ensure research subjects will not be subjected to unreasonable risk. If the FDA does not contact the sponsor with concerns or place a "clinical hold" on the trial within 30 days, the sponsor may begin the clinical trial. As a CCRC, it is vital to know that subject enrollment cannot begin until this 30-day period expires or the FDA grants early clearance.

---

The New Drug Application (NDA)

If the clinical trials (Phases I, II, and III) are successful, the sponsor will submit a New Drug Application (NDA) to the FDA. The NDA is the formal step a drug sponsor takes to ask that the FDA consider approving a new drug for marketing in the United States.

The Goal of the NDA

The FDA reviews the NDA to determine three key things:

1. Whether the drug is safe and effective for its proposed use(s), and whether the benefits of the drug outweigh the risks.
2. Whether the drug's proposed labeling (package insert) is appropriate, and what it should contain.
3. Whether the methods used in manufacturing the drug and the controls used to maintain the drug's quality are adequate to preserve the drug's identity, strength, quality, and purity.

An NDA contains all the animal and human data collected during the drug's development. For a CCRC, the data entered into Case Report Forms (CRFs) during the Phase I-III trials forms the bedrock of the clinical efficacy and safety sections of the NDA. Accuracy and completeness at the site level directly impact the approval process.

---

Medical Devices: IDE and PMA

Medical devices follow a different regulatory framework than drugs. Devices are classified into Class I (low risk), Class II (moderate risk), and Class III (high risk).

Investigational Device Exemption (IDE)

An Investigational Device Exemption (IDE) allows an investigational device to be used in a clinical study in order to collect safety and effectiveness data. This is typically required for Class III devices or new technologies before they can be marketed.

There are two categories of device studies under an IDE:

• Significant Risk (SR) Device Study: A study of a device that presents a potential for serious risk to the health, safety, or welfare of a subject (e.g., implants, life-supporting devices). SR studies require both FDA approval of an IDE application and Institutional Review Board (IRB) approval.
• Non-Significant Risk (NSR) Device Study: A study of a device that does not meet the definition of a significant risk device. NSR studies require only IRB approval and are considered to have approved IDEs without the need for a formal submission to the FDA.

Premarket Approval (PMA)

Premarket Approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury.

The PMA is the most stringent type of device marketing application required by the FDA. It must contain sufficient valid scientific evidence to assure that the device is safe and effective for its intended use(s). Like the NDA for drugs, the PMA relies heavily on the clinical data generated from IDE studies.

510(k) Clearance

For Class II devices, sponsors often use the 510(k) pathway instead of a PMA. A 510(k) is a premarket submission made to the FDA to demonstrate that the device to be marketed is at least as safe and effective, that is, "substantially equivalent," to a legally marketed device (predicate device) that is not subject to PMA. While some 510(k) submissions require clinical data, many rely solely on bench testing and preclinical comparisons.

---

The CCRC's Role in Submissions

While the sponsor is responsible for compiling and submitting INDs, NDAs, IDEs, and PMAs, the CCRC plays an essential role in generating the data that populates these submissions.

• Data Integrity: Every data point captured on a source document and transcribed to an Electronic Data Capture (EDC) system contributes to the final regulatory submission. ALCOA-C (Attributable, Legible, Contemporaneous, Original, Accurate, and Complete) standards are paramount.
• Regulatory Document Maintenance: The CCRC maintains the site's regulatory binder (Investigator Site File), ensuring all Form FDA 1572s, Financial Disclosure Forms (FDFs), CVs, and IRB approvals are current. These documents are routinely audited by sponsors to ensure the integrity of the clinical data submitted to the FDA.
• Adverse Event Reporting: Prompt and accurate reporting of Serious Adverse Events (SAEs) by the site allows the sponsor to submit timely safety reports (e.g., IND Safety Reports) to the FDA and other participating sites.

Understanding these regulatory pathways helps the CCRC appreciate the "big picture" of clinical research and reinforces the importance of meticulous data collection and adherence to the protocol.